Table 5.
Survival analyses for 94 patients with fibrillary GN without ESKD at diagnosis
| Variable | No. | Unadjusted HR (95% CI) | P | Adjusted HR Final Model (95% CI) | P |
|---|---|---|---|---|---|
| Sex | |||||
| Female | 63 | Reference | Reference | ||
| Male | 31 | 2.37 (1.32 to 4.25) | 0.004 | 3.82 (1.97 to 7.37) | <0.001 |
| eGFRa | |||||
| 1 to <30 | 41 | 5.65 (1.33 to 24.00) | 0.02 | 8.02 (1.85 to 34.75) | 0.005 |
| 30 to <45 | 21 | 4.54 (1.00 to 20.57) | 0.05 | 6.44 (1.38 to 29.99) | 0.02 |
| 45 to <60 | 9 | 1.30 (0.18 to 9.31) | 0.79 | 1.30 (0.18 to 9.38) | 0.79 |
| 60–150 | 10 | Reference | Reference | ||
| Unknown | 13 | 4.29 (0.90 to 20.35) | 0.07 | 9.57 (1.85 to 49.51) | 0.007 |
| Nephrotic range proteinuria | |||||
| Yes | 42 | 2.73 (0.94 to 7.92) | 0.06 | NS | |
| No | 17 | Reference | |||
| Unknown | 35 | 2.19 (075 to 6.44) | 0.15 | ||
| Received immunosuppression | |||||
| Yes | 28 | 1.75 (0.78 to 3.87) | 0.17 | NS | |
| No | 31 | Reference | |||
| Unknown | 35 | 2.07 (1.00 to 4.29) | 0.05 | ||
| Crescents present | |||||
| Yes | 19 | 1.95 (1.00 to 3.81) | 0.05 | NS | |
| No | 65 | Reference | |||
| Unknown | 10 | 1.16 (0.48 to 2.82) | 0.74 | ||
| FGGS >25% | |||||
| Yes | 42 | 1.54 (0.83 to 2.86) | 0.17 | NS | |
| No | 43 | Reference | |||
| Unknown | 9 | 1.02 (0.38 to 2.75) | 0.97 | ||
No., number of patients; HR, Hazard ratio; CI, confidence interval; NS, not significant in multivariable model; FGGS, focal global glomerulosclerosis.
a
eGFR was calculated with the Modification of Diet in Renal Disease equation and divided based on Kidney Disease Improving Global Outcome guidelines for CKD.